Caseware UK (AP4) 2023.0.135 2023.0.135 true2023-05-01Development of biocatalysis process technologies00truetruefalse SC425526 2023-05-01 2024-04-30 SC425526 2022-05-01 2023-04-30 SC425526 2024-04-30 SC425526 2023-04-30 SC425526 c:Director3 2023-05-01 2024-04-30 SC425526 d:CurrentFinancialInstruments 2024-04-30 SC425526 d:CurrentFinancialInstruments 2023-04-30 SC425526 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 SC425526 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 SC425526 d:ShareCapital 2024-04-30 SC425526 d:ShareCapital 2023-04-30 SC425526 c:EntityHasNeverTraded 2023-05-01 2024-04-30 SC425526 c:FRS102 2023-05-01 2024-04-30 SC425526 c:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 SC425526 c:FullAccounts 2023-05-01 2024-04-30 SC425526 c:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 SC425526 6 2023-05-01 2024-04-30 SC425526 e:PoundSterling 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure

Registered number: SC425526










Ingenza Biologics Limited








Unaudited

Financial statements

Information for filing with the registrar

For the Year Ended 30 April 2024

 
Ingenza Biologics Limited
Registered number: SC425526

Balance Sheet
As at 30 April 2024

2024
2023
Note
£
£

Fixed assets
  

Investments
 3 
350,475
350,475

  
350,475
350,475

Current assets
  

Debtors: amounts falling due within one year
 4 
7
7

  
7
7

Creditors: amounts falling due within one year
 5 
(350,472)
(350,472)

Net current liabilities
  
 
 
(350,465)
 
 
(350,465)

Total assets less current liabilities
  
10
10

  

Net assets
  
10
10


Capital and reserves
  

Called up share capital 
  
10
10

  
10
10


For the year ended 30 April 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



................................................
Jaymin Amin
Director
Date: 12 December 2024

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 
Ingenza Biologics Limited
 

 
Notes to the Financial Statements
For the Year Ended 30 April 2024

1.


General information

Ingenza Biologics Limited is a private limited liability company incorporated in Scotland, registration number SC425526. The address of the registered office and principal place of business is Roslin Innovation Centre, Charnock Bradley Building, Easter Bush Campus, Bush Farm Road, Roslin, Scotland, EH25 9RG.
The Company did not trade in either period. 
The accounts are presented in Sterling, which is the functional currency of the company. The accounts are rounded to the nearest £1. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

 
2.2

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Profit and Loss Account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.3

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Fixed asset investments





Unlisted investments

£



Cost or valuation


At 1 May 2023
350,475



At 30 April 2024
350,475




Page 2

 
Ingenza Biologics Limited
 

 
Notes to the Financial Statements
For the Year Ended 30 April 2024

4.


Debtors

2024
2023
£
£


Other debtors
7
7

7
7



5.


Creditors: Amounts falling due within one year

2024
2023
£
£

Other creditors
350,472
350,472

350,472
350,472


Page 3